Wire · opportunities
HLB Secures First FDA Approval with Acquired Bile Duct Drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
HLB's US subsidiary Elevar Therapeutics secured FDA approval for Lyrfigtu, a bile duct cancer drug acquired from Relay Therapeutics, marking HLB's first FDA-approved anticancer drug despite previous failures to approve its liver cancer drug. The approval targets adults with bile duct cancer carrying FGFR2 gene fusion mutations, with the drug planned for US launch in Q4 2026 and FDA requiring a post-approval clinical trial on dosage safety.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 21 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
Elevar’s FDA approval opens a new US market for bile duct cancer drugs, not built by you but acquired. If you work in targeted oncology therapies, now is the time to engage with US specialists preparing for launch and watch for upcoming dosage trials that may reshape safety profiles.
◆ Coverage
6 sources · first reported 21 Sep 2026 · latest 28 Sep 2026
◆ Topics